February 25, 2010 (FinancialWire) — Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has appointed Andreas Rummelt as a director of the firm. Rummelt has more than 25 years of experience in the pharmaceutical industry, primarily focusing on drug development, technical operations, quality assurance and global manufacturing strategy.

Rummelt was a member of the Executive Committee of Novartis from 2006 to 2010, where he most recently served as Group Head of Quality Assurance and Technical Operations until 2010.

He joined Sandoz Pharma in Switzerland in 1985 and held various positions of increasing responsibility in drug development. In 1994, he was appointed Head of Worldwide Technical Research and Development, a position he retained following the merger that created Novartis in 1996.

From 1999 to 2004, Rummelt served as Global Head of Technical Operations of the Novartis Pharmaceuticals Division. From 2004 to 2008, he was CEO of Sandoz, the generics division of Novartis.

Connecticut-based Alexion Pharmaceuticals is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a range of severe disease states, including hematologic and kidney diseases, transplant, cancer, and autoimmune disorders.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.